Makindo Medical Notes"One small step for man, one large step for Makindo" |
|
|---|---|
| Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
| MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
Dapagliflozin is an SGLT2 inhibitor originally developed for type 2 diabetes but now also recognised for its benefits in heart failure (HFrEF) and chronic kidney disease (CKD), independent of glycaemic control. It reduces hospitalisation for heart failure and slows CKD progression. ππ«π Always check the BNF for latest prescribing advice.
| Indication | Dose | Frequency | Route |
|---|---|---|---|
| Type 2 Diabetes Mellitus | 10 mg | OD | PO |
| Heart Failure (HFrEF) | 10 mg | OD | PO |
| Chronic Kidney Disease | 10 mg | OD | PO |
π‘ Clinical Pearl: In patients with diabetes + heart failure or CKD, dapagliflozin is often preferred even if HbA1c is at target, due to its cardio-renal benefits independent of glucose lowering.